New hope for kids with rare cancer: drug combo shows promise
NCT ID NCT06341998
First seen Sep 30, 2025 · Last updated Jun 16, 2026 · Updated 33 times
Summary
This study tested a new combination of the drug sirolimus plus chemotherapy (nab-paclitaxel, ifosfamide, and carboplatin) in 32 children with recurrent or treatment-resistant yolk sac tumor. The goal was to see if the combo could shrink tumors and improve survival. The study is complete, and results will show how well the treatment worked and how safe it was.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, 250117, China
Conditions
Explore the condition pages connected to this study.